1. Home
  2. GOF vs EVO Comparison

GOF vs EVO Comparison

Compare GOF & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guggenheim Strategic Opportunities Fund of Beneficial Interest

GOF

Guggenheim Strategic Opportunities Fund of Beneficial Interest

HOLD

Current Price

$10.49

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.96

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOF
EVO
Founded
N/A
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
1.0B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
GOF
EVO
Price
$10.49
$1.96
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
1.3M
44.2K
Earning Date
01-01-0001
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
N/A
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.39
$1.94
52 Week High
$15.20
$4.42

Technical Indicators

Market Signals
Indicator
GOF
EVO
Relative Strength Index (RSI) 32.06 25.35
Support Level N/A N/A
Resistance Level $11.02 $3.36
Average True Range (ATR) 0.10 0.10
MACD -0.03 -0.05
Stochastic Oscillator 18.10 1.02

Price Performance

Historical Comparison
GOF
EVO

About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest

Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: